AKCA - Akcea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
31.860
+3.880 (+13.87%)
As of 3:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close27.980
Open28.080
Bid31.670 x 900
Ask31.750 x 1400
Day's Range28.080 - 31.860
52 Week Range15.200 - 40.750
Volume375,209
Avg. Volume294,554
Market Cap2.731B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.378
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

    CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) --  Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).  Additional data from the Phase 2 study will be presented as a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018. The goal of the Phase 2 study was to characterize the safety and tolerability of AKCEA-APO(a)-LRx and to inform dose and dose frequency selection for the planned Phase 3 cardiovascular outcomes study.  The randomized, double-blind, placebo-controlled, dose-ranging study included 286 patients with established CVD and high Lp(a) (baseline mean of approximately 100 mg/dL [250 nmol/L] – more than three times the upper limit of normal).

  • Reuters18 days ago

    Akcea Therapeutics to cut about 10 pct of workforce

    Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood. The company said it expected to book charges of $2 million to $2.5 million in the third quarter https://www.sec.gov/Archives/edgar/data/1662524/000114036118037945/form8k.htm, as a result of the decision, which affects only U.S. employees involved in functions focused on Waylivra.

  • Cambridge's Akcea discloses layoffs after FDA drug rejection
    American City Business Journals18 days ago

    Cambridge's Akcea discloses layoffs after FDA drug rejection

    Cambridge-based Akcea Therapeutics Inc. said Thursday that it plans to lay off 10 percent of its workforce following the FDA's rejection of its rare disease drug last week. While Akcea (Nasdaq: AKCA) did not say how many people would be laid off, the company told the Business Journal in June that it had more than 200 employees. In a statement, Akcea said the company remains "very disappointed" with the FDA's decision not to approve its drug, called Waylivra, which targets a lipid disorder called familial chylomicronemia syndrome, or FCS.

  • Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?
    Motley Fool26 days ago

    Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover?

    A surprise rejection is a major setback for both partners, but not the end of the line.

  • GlobeNewswire26 days ago

    Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference

    Akcea Therapeutics, Inc.(AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview at the Wells Fargo Healthcare Conference at 4:10 p.m. ET on Wednesday, September 5, 2018 in Boston. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases.

  • Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today
    Motley Fool27 days ago

    Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today

    The FDA gives a thumbs down to their triglyceride-lowering drug Waylivra.

  • Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback
    Bloomberg27 days ago

    Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback

    Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. got a rude surprise last night after the Food and Drug Administration issued a complete response letter on their Waylivra, following a contentious vote at a May advisory committee meeting. Peer Alnylam Pharmaceuticals Inc. shares soared yesterday on Pfizer Inc.’s results for a competing treatment for the same disease, ATTR, but in the cardiomyopathy type. Many analysts covering Ionis and Akcea remain optimistic ahead of a FDA decision on Tegsedi, expected by Oct. 6.

  • Benzinga27 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Toyota Motor Corp (ADR) (NYSE: TM ) stock was trading ...

  • Benzinga27 days ago

    The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...

  • FDA rejects rare disease drug developed by Cambridge's Akcea
    American City Business Journals28 days ago

    FDA rejects rare disease drug developed by Cambridge's Akcea

    Waylivra is one of two drugs Akcea was planning to launch in the next year or two, according to Akcea President Sarah Boyce.

  • GlobeNewswire28 days ago

    Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

    Akcea Therapeutics, Inc. (AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that they received a Complete Response Letter (CRL) from the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for WAYLIVRA™(volanesorsen). “We are extremely disappointed with the FDA’s decision. Familial chylomicronemia syndrome (FCS) is an ultra-rare, devastating hereditary disease that causes unpredictable and potentially fatal acute pancreatitis, chronic complications due to permanent organ damage, and a severe impact on daily living.

  • Benzinga28 days ago

    Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves

    Multiple pharma stocks are making sympathy moves Monday in reaction to data released at the 2018 European Society of Cardiology Congress in Munich, Germany. Pfizer Inc. (NYSE: PFE ) shares are trading ...

  • Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today
    Motley Fool28 days ago

    Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today

    A competitor's data wasn't as good as investors feared.

  • MarketWatch28 days ago

    Pfizer rare-disease drug results lift its shares and those of rival

    Pfizer Inc. (PFE) shares rose just under 1% in Monday premarket trade after the company announced positive results from a late-stage trial of its drug tafamidis, which is being developed for the rare disease transthyretin amyloid cardiomyopathy. The Pfizer results were strong but "we see the door open to ALNY given key details of the study: 1) 20 mg not differentiated from 80 mg, and 2) more limited efficacy in the ATTRm population (vs wild-type) and would not be surprised to see ALNY shares trade up," said EvercoreISI analyst Josh Schimmer and Steven Breazzano, who went on to say that two rival therapies, Alnylam Pharmaceuticals Inc.'s (ALNY) patisiran and Ionis Pharmaceuticals Inc. (IONS) and Akcea Therapeutics Inc.'s (AKCA) inotersen, "will generally be safe in the neuropathy population." Alnylam shares rose 4.3% in premarket trade while Ionis and Akcea shares were inactive.

  • Is the Options Market Predicting a Spike in Akcea Therapeutics (AKCA) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in Akcea Therapeutics (AKCA) Stock?

    Investors need to pay close attention to Akcea Therapeutics (AKCA) stock based on the movements in the options market lately.

  • Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO?
    Motley Foollast month

    Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO?

    There's a new public company with an ATTR drug in mid-stage development.

  • Akcea Therapeutics Soars as It Readies Its First Drug Launch
    Motley Foollast month

    Akcea Therapeutics Soars as It Readies Its First Drug Launch

    But the real opportunity may be with Ionis Pharmaceuticals.

  • Alnylam drug approval marks watershed moment for gene-silencing field
    American City Business Journalslast month

    Alnylam drug approval marks watershed moment for gene-silencing field

    Alnylam is one of several local biotechs developing drugs based on Nobel Prize-winning technology known as RNA interference.

  • Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses
    Motley Foollast month

    Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses

    It's hard to make a profit that way, but the situation seems temporary as the biotech waits for FDA approval of two drugs.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Foollast month

    3 Biotech Stocks With Major Catalysts Incoming

    Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.

  • Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass.
    American City Business Journalslast month

    Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass.

    Investors betting on Tesla’s stock stumbling took a beating this week when shares in the company rallied after CEO Elon Musk tweeted that he was considering taking the company private.

  • Benzinga2 months ago

    The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...

  • GlobeNewswire2 months ago

    Akcea Reports Financial Results and Highlights for Second Quarter 2018

    TEGSEDI™ Approved in European Union $382 million to fund the company through key milestones in 2019. Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com. CAMBRIDGE, Mass., Aug. 06, ...

  • ACCESSWIRE2 months ago

    Akcea Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Akcea Therapeutics, Inc. (NASDAQ: AKCA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...

  • PR Newswire2 months ago

    Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

    TEGSEDI has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). TEGSEDI is also the subject of a pending new drug application in the U.S. and Canada.